February 25, 2021

Co-operation with PharmaLegacy

OncoBone is pleased to announce co-operation with the Shanghai-based preclinical CRO PharmaLegacy. In the co-operation OncoBone will provide its expertise to support PharmaLegacy in expanding its client-base especially in Europe.

Jussi Halleen, CEO of OncoBone says: “I know PharmaLegacy from 10 years back when I visited them in Shanghai. I was impressed then and am even more impressed today about their continuing success in preclinical CRO business. I am convinced that OncoBone is in an excellent position to help PharmaLegacy expanding their business further, especially in our key expertise fields oncology and bone diseases.”

Michael Zhang, VP of PharmaLegacy adds: “We are very impressed about the high reputation of OncoBone representatives in the fields of oncology and bone diseases. PharmaLegacy has high expectations for OncoBone for successful promotion of especially our oncology and non-human primate models in European markets.”